Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

578 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage.
Fluckiger A, Daillère R, Sassi M, Sixt BS, Liu P, Loos F, Richard C, Rabu C, Alou MT, Goubet AG, Lemaitre F, Ferrere G, Derosa L, Duong CPM, Messaoudene M, Gagné A, Joubert P, De Sordi L, Debarbieux L, Simon S, Scarlata CM, Ayyoub M, Palermo B, Facciolo F, Boidot R, Wheeler R, Boneca IG, Sztupinszki Z, Papp K, Csabai I, Pasolli E, Segata N, Lopez-Otin C, Szallasi Z, Andre F, Iebba V, Quiniou V, Klatzmann D, Boukhalil J, Khelaifia S, Raoult D, Albiges L, Escudier B, Eggermont A, Mami-Chouaib F, Nistico P, Ghiringhelli F, Routy B, Labarrière N, Cattoir V, Kroemer G, Zitvogel L. Fluckiger A, et al. Among authors: zitvogel l. Science. 2020 Aug 21;369(6506):936-942. doi: 10.1126/science.aax0701. Science. 2020. PMID: 32820119 Free article.
Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).
Merad M, Angevin E, Wolfers J, Flament C, Lorenzi I, Triebel F, Escudier B, Zitvogel L. Merad M, et al. Among authors: zitvogel l. J Immunother. 2000 May-Jun;23(3):369-78. doi: 10.1097/00002371-200005000-00010. J Immunother. 2000. PMID: 10838666 Clinical Trial.
Exosomes in cancer immunotherapy: preclinical data.
Andre F, Andersen M, Wolfers J, Lozier A, Raposo G, Serra V, Ruegg C, Flament C, Angevin E, Amigorena S, Zitvogel L. Andre F, et al. Among authors: zitvogel l. Adv Exp Med Biol. 2001;495:349-54. doi: 10.1007/978-1-4615-0685-0_49. Adv Exp Med Biol. 2001. PMID: 11774591 Review. No abstract available.
Malignant effusions and immunogenic tumour-derived exosomes.
Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tursz T, Amigorena S, Raposo G, Angevin E, Zitvogel L. Andre F, et al. Among authors: zitvogel l. Lancet. 2002 Jul 27;360(9329):295-305. doi: 10.1016/S0140-6736(02)09552-1. Lancet. 2002. PMID: 12147373
Tumor-derived exosomes: a new source of tumor rejection antigens.
André F, Schartz NE, Chaput N, Flament C, Raposo G, Amigorena S, Angevin E, Zitvogel L. André F, et al. Among authors: zitvogel l. Vaccine. 2002 Dec 19;20 Suppl 4:A28-31. doi: 10.1016/s0264-410x(02)00384-5. Vaccine. 2002. PMID: 12477425 Review.
Exosomes for immunotherapy of cancer.
Chaput N, Schartz NE, Andre F, Zitvogel L. Chaput N, et al. Among authors: zitvogel l. Adv Exp Med Biol. 2003;532:215-21. doi: 10.1007/978-1-4615-0081-0_17. Adv Exp Med Biol. 2003. PMID: 12908560 Review.
578 results